All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 8, 2023
Home » Topics » Conferences

Conferences
Conferences RSS Feed RSS

SDZ-266806: A novel squalene synthase inhibitor

Aug. 30, 1996
No Comments

New agents for use in transplantation

Aug. 30, 1996
No Comments

FR-173657: Fujisawa's bradykinin B2 antagonist

Aug. 23, 1996
No Comments

UPF-596 described as a novel glutamate antagonist

Aug. 23, 1996
No Comments

Eisai's squalene synthase inhibitor and prodrug

Aug. 23, 1996
No Comments

KF-20444: Kyowa Hakko's novel antirheumatic agent

Aug. 23, 1996
No Comments

Pfizer investigates enantiomeric profiles of citalopram, fluoxetine

Aug. 16, 1996
No Comments

Lamotrigine, valproate tested in mood disorders

Aug. 16, 1996
No Comments

BTS-73947: new D1/D5 antagonist from Knoll

Aug. 16, 1996
No Comments

Roche profiles pharmacokinetics, pharmacodynamics of new benzodiazepine

Aug. 16, 1996
No Comments
Previous 1 2 … 2947 2948 2949 2950 2951 2952 2953 2954 2955 … 2976 2977 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 8, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 8, 2023.
  • Medical cannabis in blister pack of capsules

    Zelira’s stock triples as cannabinoid outperforms Lyrica in pain

    BioWorld
    Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed...
  • Cerebellum, brain stem, spinal cord

    Reprocell reports mixed results for phase II Stemchymal trial in spinocerebellar ataxia

    BioWorld
    Regenerative medicine product Stemchymal, an allogeneic adipose-derived mesenchymal stem cell treatment, missed the primary efficacy endpoints in two phase II...
  • Gavel and First Amendment

    Citing US constitutional violations, Merck the first to challenge the IRA

    BioWorld
    The question wasn’t if, but when and how, someone would challenge the Medicare negotiation provision laid out in the Inflation Reduction Act (IRA) that was signed...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing